This month, TMCi is welcoming a slew of health tech and cancer innovators who will advance solutions in medicine over the next several months. Image via TMC.edu

The Texas Medical Center has announced the latest cohorts of its two health tech accelerators.

The Texas Medical Center Innovation has named eight companies that are in the Spring 2023 Accelerator for HealthTech cohort. TMCi also announced 21 participants are set to join the 2023 Accelerator for Cancer Therapeutics cohort. Both programs connect the entrepreneurs and innovators to experts at TMC’s campuses to solve unmet clinical needs and reach the next business milestone.

“At TMC Innovation, we start with a promise of uniting cutting-edge innovators in science and medicine with the talent found at the Texas Medical Center," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our 2023 cohort members are tackling some of the most critical issues we face today in healthcare.

"We are excited to welcome a new group of researchers and companies to the TMC Innovation Factory, and to work collaboratively with our new cohort members and our partners from across the Texas Medical Center," she continues.

Here's what 2023 can expect from these two program's cohorts.

TMCi HealthTech Accelerator

The six-month, twice annual HealthTech Accelerator — originally launched in 2014 with over 225 alumni companies — focuses on digital health and medical device startups. The spring cohort are addressing solutions across maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

"Uniting talented professionals from across the globe provides a unique opportunity for innovation, creativity, and development in diverse areas of expertise," says Devin Dunn, head of the Accelerator for Healthtech at TMCi, in the release. "Our tailored program maximizes participants' experiences while determining the best match between these companies and Texas Medical Center’s network."

The cohort was selected following a November bootcamp that introduced potential startup members to the TMC and the Houston health care community.

The following companies will join the TMC this month:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.

Accelerator for Cancer Therapeutics

The TMC has announced the 21 researchers and companies tapped to join the 2023 Accelerator for Cancer Therapeutics.

The nine-month program, funded by the Cancer Prevention and Research Institute of Texas in partnership with the Gulf Coast Consortia and the University of Texas Medical Branch, supports investigators and early-stage biotechnology companies with innovative solutions in cancer therapeutics. Participants will be mentored by a group of scientific, business, and innovation leaders to ultimately be positioned to apply for grants and pitch to investors and corporate partners to further the development of their innovative cancer solutions.

“For this third cohort, we focused on a strategic and extensive recruitment process, including the evaluation of 1,679 cancer research projects. From 56 applications, we selected 21 participants that will gain access to valuable resources, integrated training and mentorship to prepare for clinical trials,” says Ahmed AlRawi, program manager of Accelerator for Cancer Therapeutics, in the release. “Our 2023 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. We are excited to continue the momentum and build off the successes of our previous years.”

Forty-five participants have gone through the accelerator program since its launch in 2021, and collectively, the entrepreneurs have raised more than $90 million in funding and three projects are in the clinic.

The 2023 cohort participants are focused on a wide range of therapeutic assets, including small molecule, antibody, peptide/protein, cell therapy, and other. The 2023 cohort kicks off their nine-month program in January.

The participants include:

  1. Dr. Amit K. Tripathi – UNT-Health Science Center
  2. Dr. Darshan Gandhi (ImproveBio, LLC)
  3. Dr. Frank McKeon (Tract Pharmaceutical) – University of Houston
  4. Dr. Hemanta Baruah (Aakha Biologics)
  5. Dr. Joshua Gruber – UT-Southwestern
  6. Dr. Kyoji Tsuchikama – UT Health Science Center-Houston
  7. Dr. Maralice Conacci Sorrell – UT-Southwestern
  8. Dr. Michael Buszczak – UT-Southwestern
  9. Dr. Nadezhda (Nadia) German -Texas Tech-Lubbock
  10. Dr. Parsa Modareszadeh (HemePro Therapeutics) – UT-Dallas
  11. Dr. Robert Kruse (HydroGene Therapeutics)
  12. Dr. Xiang Zhang – Baylor College of Medicine
  13. Dr. Youngwook Won (Singular Immune, Inc.)
  14. Dr. Zhi-Ping Liu (Raphael Pharmaceutical LLC) – UT-Southwestern
  15. Dr. Jonathan Arambula (InnovoTEX Inc.)
  16. Dr. Isaac Chan – UT-Southwestern
  17. Dr. Olga Granaturova (Ruptakine Inc.) – UT Health Science Center-Houston
  18. Dr. Jim Song (Tranquility Biodesign) – Texas A&M-College Station
  19. Dr. Rosa Selenia Guerra-Resendez (Quetzal Bio, LLC) – Rice University
  20. Dr. Cassian Yee (Mongoose Bio, LLC) – UT-MD Anderson Cancer Center
  21. Dr. Manjeet Rao (Niragen, Inc.) – UT Health Science Center-San Antonio


These nine companies are headed to Houston. Photo courtesy of TMC

TMC Innovation names 9 companies to its latest bootcamp

coming soon to Hou

Nine startups hailing from as far away as Sydney, Australia, are en route to Houston to participate in a week-long program at the Texas Medical Center's Innovation Factory.

The 2022 TMCi Accelerator for HealthTech Bootcamp is looking to accelerate these startups, which specialize in health tech innovation across the spectrum — maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

“One of the things I love about Bootcamp is the opportunity to showcase the diversity of innovation our ecosystem attracts," says Devin Dunn, head of the Accelerator for Healthtech, in a news release. "The breadth of clinical and operational expertise in our Medical Campus creates a unique learning ground, truly unmatched. Our tailored accelerator program allows for an experience that is personalized to each company’s stage, specialty and growth objectives.”

After the week at TMC, a smaller group of startups will be accepted into the TMCi Accelerator, a six-month program focused on maturing strategic relationships.

“Startup companies who are impacting the future of healthcare need clinical evidence to validate their value proposition and grow their businesses," says Emily Reiser, associate director of TMC Innovation, in the release. "Our platform at the TMC sources the best talent from around the world, performs rigorous diligence, and brings entrepreneurs together with our dedicated network to drive value for each stakeholder. We are seeing this value proposition resonate with entrepreneurs, including international companies preparing to enter the US market”

The nine startups that will be participating in the program, per the news release, include:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • Echo IQ, headquartered in Sydney, is a screening program that applies a proprietary algorithm to produce risk assessments for patients using their echocardiographic measurements.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston tech companies recognized for creating top inventions of the year

best of the rest

Innovations from three Houston companies have been crowned among the top inventions of the year.

Time magazine’s "200 Best Inventions of 2024" identified top innovations across consumer goods, home health, robotics, sustainability, and two dozen other categories.

Fervo Energy, a provider of geothermal power, was recognized the Green Energy category for its FervoFlex system. As Time explains, the system enables horizontal drilling into hot rock under the earth’s surface and pumping in water to generate hot water and steam. The geothermal energy that’s produced can be stored and released for future use by Fervo customers.

Jack Norbeck, Fervo’s co-founder and chief technology officer, predicts that by 2050, geothermal energy will become “the backbone of the decarbonized energy system.”

In September, Fervo secured a $100 million bridge loan for the first phase of its ongoing Cape Station project in Utah, which is being touted as the world’s largest geothermal energy plant. Slated for completion in June 2026, this initial phase is expected to generate 90 megawatts of renewable energy. Ultimately, the plant is supposed to supply 400 megawatts of clean energy by 2028 for customers in California.

Time also lauded NanoTech Materials among its Manufacturing and Materials honorees for its Insulative Ceramic Particle. This powder can be added to materials like drywall or shingles to improve fire resistance and decrease heat penetration, according to Time. NanoTech’s Wildfire Shield coating for buildings contains the powder. Wildfire Shield prevents damage to materials and harm from noxious smoke.

NanoTech’s other product, Cool Roof Coat, is painted on a building to decrease HVAC use. This year, NanoTech moved into a 43,000-square-foot space in Katy, Texas, and brought on new partners that expanded the company's reach in the Middle East and Singapore.

The third Houston company to be praised by Time is BiVACOR — named to its Experimental category of the list. This year, the company’s artificial heart has kept three U.S. patients alive long enough to wait for donor organs, according to Time, the first of these operations took place this summer in Houston.

Dr. William Cohn, chief medical officer of BiVACOR, previously told InnovationMap that while the Total Artificial Heart is being used currently as a "bridge-to-transplant" device, he believes it has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

The full list of this year's top inventions is available online.

Houston researchers secure funding for superconductivity project

fresh funding

Researchers at the Department of Physics at the University of Houston and Texas Center for Superconductivity have received a second-year funding from global leader in business of invention Intellectual Ventures to continue their work on exploring superconductivity,

The project, which is led by Paul C. W. Chu, T.L.L. Temple Chair of Science, professor of physics and founding director of the TcSUH and assistant professor of physics and a new TcSUH principal investigator Liangzi Deng, has been awarded $767,000 to date.

“Working with IV gives us the freedom known for scientific pursuit and at the same time provides intellectual guidance and assistance in accord with the mission goal,” Chu says in a news release.

The researchers are working on making superconductivity easier to achieve. At room temperature and normal atmospheric pressure is where the researchers are looking to simplify superconductivity. One finding from Chu and Deng’s team is called pressure-quench protocol, or PQP.The PQP will help maintain key properties (like superconductivity) in certain materials after the high pressure needed to create them is removed.

“Intellectual Ventures funded this research because Paul Chu is one of the acknowledged thought leaders in the area of superconductivity with a multi-decade track record of scientific innovation and creativity,” Brian Holloway, vice president of IV’s Deep Science Fund and Enterprise Science Fund, adds. “The work led by Chu and Deng on pressure quenching could result in game-changing progress in the field. We are very excited about the preliminary results from the first year and we look forward to continuing this collaboration.”

The project showed early success the first year, as the research used a special system to synthesize materials under high temperatures and pressure. The second-year projects will include the investigation of pressure-induced/enhanced superconductivity in cuprates and hydrides.

“If successful, UH will once again break the record for the highest superconducting Tc at atmospheric pressure,” Deng says in the release. “Additionally, we will collaborate closely with theorists to uncover the mechanism of PQP. Our research has far-reaching implications, with the potential to extend beyond superconductors to other material systems.”

------

This article originally ran on EnergyCapital.